- Home
- NTB vs BLTE Comparison
NTB vs BLTE Comparison
Compare NTB & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- BLTE
- Stock Information
- Founded
- NTB 1858
- BLTE 2018
- Country
- NTB Bermuda
- BLTE United States
- Employees
- NTB N/A
- BLTE N/A
- Industry
- NTB Commercial Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- NTB Finance
- BLTE Health Care
- Exchange
- NTB Nasdaq
- BLTE Nasdaq
- Market Cap
- NTB 1.9B
- BLTE 2.1B
- IPO Year
- NTB 2016
- BLTE 2022
- Fundamental
- Price
- NTB $46.46
- BLTE $63.22
- Analyst Decision
- NTB Buy
- BLTE Strong Buy
- Analyst Count
- NTB 4
- BLTE 4
- Target Price
- NTB $49.25
- BLTE $96.67
- AVG Volume (30 Days)
- NTB 164.7K
- BLTE 60.2K
- Earning Date
- NTB 07-25-2025
- BLTE 08-08-2025
- Dividend Yield
- NTB 3.76%
- BLTE N/A
- EPS Growth
- NTB 7.68
- BLTE N/A
- EPS
- NTB 4.81
- BLTE N/A
- Revenue
- NTB $585,277,000.00
- BLTE N/A
- Revenue This Year
- NTB $3.10
- BLTE N/A
- Revenue Next Year
- NTB $0.34
- BLTE N/A
- P/E Ratio
- NTB $9.61
- BLTE N/A
- Revenue Growth
- NTB 1.89
- BLTE N/A
- 52 Week Low
- NTB $33.04
- BLTE $43.70
- 52 Week High
- NTB $46.89
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- NTB 69.93
- BLTE 56.22
- Support Level
- NTB $45.89
- BLTE $56.10
- Resistance Level
- NTB $46.89
- BLTE $64.20
- Average True Range (ATR)
- NTB 0.75
- BLTE 2.56
- MACD
- NTB 0.15
- BLTE 0.56
- Stochastic Oscillator
- NTB 90.57
- BLTE 87.90
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.